Long-acting risperidone compared with oral olanzapine and haloperidol depot in schizophrenia: a Belgian cost-effectiveness analysis

Diana De GraeveJoseph Peuskens


Patients with schizophrenia suffer numerous relapses and rehospitalizations that are associated with high direct and indirect medical expense. Suboptimal therapeutic efficacy and, in particular, problems with compliance are major factors leading to relapse. Atypical antipsychotic agents offer improved efficacy and a lower rate of extrapyramidal adverse effects compared with conventional antipsychotic drugs. Long-acting intramuscular risperidone combines these benefits with improvements in compliance associated with depot injections. To assist decision making regarding the place of long-acting risperidone in therapy, a cost-effectiveness analysis of strategies involving first-line treatment with long-acting risperidone, oral olanzapine or depot haloperidol was performed from the perspective of the Belgian healthcare system. A decision tree model was created to compare the cost effectiveness of three first-line treatment strategies in a sample of young schizophrenic patients who had been treated for 1 year and whose disease had not been diagnosed for longer than 5 years. The model used a time horizon of 2 years, with health state transition probabilities, resource use and cost estimates derived from clinical trials, expert opinio...Continue Reading


Jun 1, 1994·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·T R Barnes, D A Curson
May 1, 1997·Health Economics·M J BuxtonM Vray
Jan 1, 1997·The Psychiatric Quarterly·P Weiden, W Glazer
Feb 7, 1998·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·J M KaneN R Schooler
Apr 2, 1998·Clinical Therapeutics·A DaviesI Schweitzer
Apr 2, 1998·Clinical Therapeutics·A DaviesI Schweitzer
Nov 26, 1998·The British Journal of Psychiatry : the Journal of Mental Science·P V TranC M Beasley
Dec 16, 1998·Schizophrenia Bulletin·M De HertJ Peuskens
Jan 1, 1999·American Journal of Health-system Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists·D B MooreR R Conley
Jun 6, 1998·PharmacoEconomics·R H Foster, K L Goa
Oct 28, 1999·PharmacoEconomics·R H Foster, K L Goa
May 31, 2001·Acta Psychiatrica Scandinavica·L J Bosveld-van HaandelR J van den Bosch
Jan 5, 2002·The New England Journal of Medicine·John G CsernanskyUNKNOWN Risperidone-USA-79 Study Group
Jun 5, 2003·The American Journal of Psychiatry·John M KaneKeith Karcher
Jul 16, 2003·Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research·John D Graham
Jan 20, 2004·CNS Drugs·Tracy Swainston Harrison, Karen L Goa
Jun 16, 2004·European Psychiatry : the Journal of the Association of European Psychiatrists·Robert A LasserMartin Turner
Jun 18, 2004·International Clinical Psychopharmacology·Martin TurnerMariëlle Eerdekens
Feb 9, 2006·Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research·P LecomteU Persson

❮ Previous
Next ❯


Mar 3, 2006·Advances in Therapy·Albert I WertheimerRichard A Levy
Feb 20, 2013·The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care·Simon FreyTom Stargardt
Feb 26, 2014·Expert Review of Pharmacoeconomics & Outcomes Research·Birgitta von SchéeleAnita Patel
Dec 18, 2007·Current Medical Research and Opinion·B M S HeegB A Van Hout
Mar 16, 2007·Acta Psychiatrica Scandinavica·H A Nasrallah
Jul 21, 2011·Nordic Journal of Psychiatry·Eva LindströmChristophe Sapin
Jul 10, 2010·Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research·Li YangPeng Dong
Jun 11, 2011·Journal of the American Psychiatric Nurses Association·Michael J Rice
Jan 20, 2018·Expert Review of Pharmacoeconomics & Outcomes Research·Bertalan NémethBalázs Nagy
Mar 20, 2010·The Cochrane Database of Systematic Reviews·Katja KomossaStefan Leucht
Sep 6, 2013·Journal of Medical Economics·Thomas R Einarson, Michiel E H Hemels
Jun 15, 2019·Expert Review of Pharmacoeconomics & Outcomes Research·Ben F M WijnenJoran Lokkerbol
Jul 21, 2012·Expert Review of Pharmacoeconomics & Outcomes Research·Pierre Chue, James Chue
Aug 22, 2018·Journal of Market Access & Health Policy·Junwen ZhouMondher Toumi
Mar 8, 2020·PharmacoEconomics·Huajie JinSarah Byford
Jun 22, 2021·Journal of Controlled Release : Official Journal of the Controlled Release Society·Adam J S McCartanRandall J Mrsny

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here